Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report ...

Chuck Davis, Mark Zuckerberg, Jamie Dimon, and Max de Groen were among other top executives who sold their stake in their ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Many of America’s wealthiest business leaders have lost millions — if not billions — of dollars in net worth since the start of the year, as President Donald Trump’s policies hit markets. But some ...

Meta Platforms Chief Executive Officer (CEO) Mark Zuckerberg and JPMorgan Chase & Co. CEO Jamie Dimon were among eight other top executives who sold their shares before US President Donald Trump ...

Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with ...

We recently published a list of Why These 10 Firms Recorded Double-Digit Gains Last Week. In this article, we are going to ...

We recently published a list of These 10 Firms Topped Wednesday’s Trading. In this article, we are going to take a look at ...